Is Lexapro (escitalopram) an appropriate medication to initiate for generalized anxiety disorder?

Is Lexapro Appropriate for Generalized Anxiety Disorder?

Yes, Lexapro (escitalopram) is an appropriate and FDA-approved first-line medication for initiating treatment of generalized anxiety disorder in adults and children 7 years and older. 1

FDA-Approved Indication

Lexapro is specifically FDA-approved for the treatment of Generalized Anxiety Disorder (GAD) in:

• Adults (18 years and older) 1
• Children and adolescents 7 years of age and older 1

The safety and effectiveness have been established through adequate and well-controlled studies, with an 8-week flexible-dose trial (10-20 mg daily) demonstrating superiority over placebo 1.

Evidence of Efficacy

Acute Treatment

• Escitalopram demonstrates robust efficacy in reducing anxiety symptoms, with statistically significant improvement over placebo beginning at weeks 1-2 and continuing through 8 weeks of treatment 2
• In pooled analyses of multiple trials, escitalopram 10-20 mg/day showed consistent superiority to placebo on the Hamilton Anxiety Scale (HAMA) total score 2
• Response rates are substantial, with 75.9% of patients achieving response (Clinical Global Impressions-Improvement score ≤2) in long-term studies 3

Pediatric Population

• In children and adolescents aged 7-17 years, escitalopram significantly reduced anxiety symptoms compared to placebo (mean PARS severity difference = -1.42, p=0.028) 4
• The medication was well-tolerated with discontinuation rates due to adverse events similar to placebo 4
• For adolescents specifically (ages 12-17), escitalopram showed superior efficacy with mean PARS change of -8.65 versus -3.52 for placebo (p=0.005) 5

Long-Term Efficacy

• Escitalopram prevents relapse in GAD patients, with only 19% relapsing on escitalopram versus 56% on placebo over 24-76 weeks (p<0.001) 6
• The risk of relapse was 4.04 times higher for placebo-treated patients 6
• Continued improvement occurs with long-term treatment, with 92% of completers achieving response status at 24 weeks 3

Dosing Strategy

Adults

• Start at 10 mg once daily 1
• May increase to 20 mg daily after at least 1 week if needed 1
• Elderly patients should remain at 10 mg daily due to 50% increase in half-life 1

Pediatric Patients (7-17 years)

• Start at 10 mg once daily 1
• May increase to 20 mg daily after at least 3 weeks 1
• Regular monitoring of weight and growth is recommended 1

Tolerability Profile

Escitalopram demonstrates favorable tolerability compared to other anxiolytics:

• Discontinuation rates due to adverse events (7%) are not significantly different from placebo (5%) 7
• Better tolerated than venlafaxine XR, which had 13% discontinuation versus 7% for escitalopram 7
• Mean weight gain over 24 weeks is modest at 3.0 pounds 3
• Discontinuation symptoms during tapered withdrawal are low, primarily dizziness (10-12%), nervousness (2-6%), and insomnia (2-6%) 6

Position in Treatment Guidelines

Current expert consensus identifies escitalopram as a first-line agent for GAD:

• Recommended alongside sertraline as preferred SSRIs for GAD, particularly in older adults 8
• Listed among the most effective treatments for GAD along with duloxetine, pregabalin, quetiapine, and venlafaxine 9
• SSRIs including escitalopram are covered by national health insurance in Japan for anxiety disorders 10

Critical Safety Considerations

Black Box Warning

• Increased risk of suicidal thoughts and actions in patients 24 years and younger, especially within the first few months of treatment or when dose is changed 1
• Close monitoring is essential, with attention to new or worsening depression, anxiety, agitation, panic attacks, irritability, or suicidal ideation 1

Contraindications

• Absolute contraindications include concurrent MAOI use (or within 14 days), pimozide use, and known allergy to escitalopram or citalopram 1
• Do not start MAOIs for at least 14 days after stopping Lexapro 1

Special Populations

• Pregnancy: May cause neonatal complications including prolonged hospitalization, respiratory support, feeding difficulties, and persistent pulmonary hypertension of the newborn when used in later pregnancy 1
• Breastfeeding: Escitalopram passes into breast milk; monitor infants for excess sedation, restlessness, agitation, poor feeding, and poor weight gain 1
• Elderly patients: Higher risk for hyponatremia; use reduced dose of 10 mg daily 1

Common Pitfalls to Avoid

• Do not exceed 10 mg daily in elderly patients due to altered pharmacokinetics 1
• Monitor children and adolescents closely for suicidal ideation, particularly during the first few months 1
• Consider CYP2C19 phenotype in adolescents, as variation significantly affects escitalopram pharmacokinetics and may influence dosing requirements 5
• Avoid abrupt discontinuation; taper gradually to minimize discontinuation symptoms 6